AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
Novel JEL™ Technology for Periocular Administration COSTA MESA, Calif., May 22, 2023 (GLOBE NEWSWIRE) — AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun a Phase 1 trial and completed dosing the first cohort of patients diagnosed with wet age-related macular degeneration (wAMD), and/or diabetic macular edema (DME). “We are very excited […]